Jefferies Believes Zoetis (NYSE: ZTS) Won’t Stop Here

By Austin Angelo

In a report released today, Ian Hilliker from Jefferies reiterated a Buy rating on Zoetis (NYSE: ZTS), with a price target of $96. The company’s shares closed yesterday at $83.96, close to its 52-week high of $85.73.

According to TipRanks.com, Hilliker is a 1-star analyst with an average return of -1.7% and a 50.0% success rate. Hilliker covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on Zoetis is Moderate Buy and the average price target is $86.50, representing a 3.0% upside.

In a report issued on April 5, Credit Suisse also reiterated a Buy rating on the stock with a $89 price target.

Zoetis’ market cap is currently $40.82B and has a P/E ratio of 47.98. The company has a book value ratio of 23.0596.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services.These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.The firm provides its services though five categories namely, anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceuticals. The company was founded in July 2012 and is headquartered in New York, NY.